The bifidogenic growth stimulator inhibits the growth and respiration of Helicobacter pylori

Helicobacter

Volumn 15, Issue 5, 2010, Pages 422-429

  Nagata, Kumiko ^a   Inatsu, Sakiko ^b   Tanaka, Mamoru ^c   Sato, Harumi ^a   Kouya, Tomoaki ^d   Taniguchi, Masayuki ^d   Fukuda, Yoshihiro ^e  

^a SENRI KINRAN UNIVERSITY   (Japan)

^b Toyo College of Food Technology   (Japan)

^c Miyairisan Pharmaceutical Co Ltd   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

1,4 dihydroxy 2 naphthoic acid; Helicobacter pylori; minimum inhibitory concentration; propionibacteria; quinone; respiration

Indexed keywords

1,4 DIHYDROXY 2 NAPHTHOIC ACID; ADENOSINE TRIPHOSPHATE; CLARITHROMYCIN; DRINKING WATER; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

AGAR DILUTION; ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM; CELL RESPIRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; HELICOBACTER PYLORI; INTESTINE FLORA; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OXYGEN ELECTRODE; PRIORITY JOURNAL; PROPIONIBACTERIUM;

ANIMALS; ANTI-BACTERIAL AGENTS; HELICOBACTER PYLORI; MALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NAPHTHOLS; OXYGEN; PROPIONIBACTERIUM;

BIFIDOBACTERIUM; HELICOBACTER PYLORI; MUS; NEGIBACTERIA; PROPIONIBACTERIUM;

EID: 77956555889     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00789.x     Document Type: Article

References (37)

1. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990 161: 626 633.
2. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr., Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992 116: 705 708.
3. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991 325: 1127 1131.
4. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 354: 784 789.
5. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990 335: 1233 1235.
6. Asaka M, Sato K, Sugano K, Sugiyama T, Takahashi S, Fukuda Y, Ota H, Murakami K, Kimura K, Shimoyama T. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001 6: 177 186. (Pubitemid 32843601)
7. Lee JH, Shin JH, Roe IH, Sohn SG, Lee JH, Kang GH, Lee HK, Jeong BC, Lee SH. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005 49: 1600 1603.
8. Wermeille J, Cunningham M, Dederding JP, et al. Failure of Helicobacter pylori eradications: is poor compliance the main cause? Gastroenterol Clin Biol 2002 26: 216 219.
9. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1990 12: 19 26.
10. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007 45: 4006 4010.
11. Murakami K, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato J, Abe H, Akira T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002 16: 1933 1938.
12. Inatsu S, Ohsaki A, Nagata K. Idebenone acts against Helicobacter pylori by inhibiting its respiration. Antimicrob Agents Chemother 2006 50: 2237 2239.
13. Gillis JC, Benfield P, McTavish D. Idebenone. Drugs Aging 1994 5: 133 152.
14. Mowat D, Kirdy DM, Kamath KR, Kan A, Thorburn DR, Christodoulou J. Respiratory chain complex III (correction of complex) in deficiency with pruritus. J Pediatr 1999 134: 352 354.
15. Nz-Nagy I. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: review. Arch Gerontol Geriatr 1990 11: 177 186.
16. Rustin P, von Kleist-Retzow JC, Chantrel-Groussar K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friendreich's ataxia. Lancet 1999 354: 477 479.
17. Hiratsuka T, Furihata K, Ishikawa J, Yamashita H, Itoh N, Seto H, Dairi T. An alternative menaquinone biosynthetic pathway operating in microorganism. Science 2008 321: 1670 1673.
18. Isawa K, Hojo K, Yoda N, et al. Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3. Biosci Biotechnol Biochem 2002 66: 679 681.
19. Kaneko T, Mori H, Iwata M, Meguro S. Growth stimulator for bifidobacteria produced by Propionibacterium freudenreichii and several intestinal bacteria. J Dairy Sci 1994 77: 393 404.
20. Mori H, Sato Y, Takemoto N, Kamiyama T, Yoshikawa Y, Meguro S, Sato H, Kaneko T. Isolation and structural identification of bifidogenic growth stimulator produced by Propionibacterium freudenreichii. J Dairy Sci 1997 80: 1959 1964.
21. Yamazaki S, Kano K, Ikeda T, Isawa K, Kaneko T. Mechanistic study on the roles of a bifidogenic growth stimulator based on physicochemical characterization. Biochim Biophys Acta 1998 1425: 516 526.
22. Yamazaki S, Kano K, Takemoto N, Kaneko K. 2-Amino-3-carboxy-1,4- naphthoquinone affects the end-product profile of bifidobacteria through the mediated oxidation of NAD(P)H. Appl Microbiol Biotechnol 2002 59: 72 8.
23. Hojo K, Yoda N, Tsuchita H, Ohtsu T, Seki K, Takemoto N, Murayama T, Iino H. Effect of ingested culture of Propionibacterium freudenreichii ET-3 on fecal microflora and stool frequency in healthy females. Biosci Microflora 2002 21: 115 120.
24. Satomi K, Kurihara H, Isaka K, Mori H, Kaneko T. Effect of culture-powder of Propionibacterium freudenreichii ET-3 on fecal microflora of normal adults. Biosci Microflora 1999 18: 27 30.
25. Nagata K, Sone N, Tamura T. Inhibitory activities of lansoprazole against respiration in Helicobacter pylori. Antimicrob Agents Chemother 2001 45: 1522 1527.
26. Nagata K, Hirai K-I, Koyama J, Wada Y, Tamura T. Antimicrobial activity of novel furanonaphthoquinone analogs. Antimicrob Agents Chemother 1998 42: 700 702.
27. Kouya T, Misawa K, Horiuchi M, Nakayama E, Deguchi H, Tanaka T, Taniguchi M. Production of extracellular bifidogenic growth stimulator by anaerobic and aerobic cultivations of several propionibacterial strains. J Biosci Bioeng 2007 103: 464 471.
28. Nagata K, Nagata Y, Sato T, Fujino MA, Nakajima K, Tamura T. L-serine D-and L-proline and alanine as respiratory substrates of Helicobacter pylori: correlation between in vitro and in vivo amino acid levels. Microbiology 2003 149: 2023 2030.
29. Markwell MAK, Haas SM, Tolbert NE, Bieber LL. Protein determination in membrane and lipoprotein samples. Methods Enzymol 1981 72: 1920 1931.
30. Wang G, Maier RJ. An NADPH quinone reductase of Helicobacter pylori play an important role in oxidative stress resistance and host colonization. Infect Immun 2004 72: 1391 1396.
31. Nagata K, Tsukita S, Tamura T, Sone N. A cb-type cytochrome c oxidase terminates the respiratory chain in Helicobacter pylori. Microbiology 1996 142: 1757 1763.
32. Soballe B, Poole RK. Microbial ubiquinone: multiple roles in respiration, gene regulation and oxidative stress management. Microbiology 1999 145: 1817 1830.
33. Marcelli SW, Chang HT, Chapman T, Chalk PA, Miles RJ, Poole RK. The respiratory chain of Helicobacter pylori: identification of cytochromes and the effects of oxygen on cytochrome and menaquinone levels. FEMS Microbiol Lett 1996 138: 59 64.
34. Moss CW, Lambert-Fair MA, Nicholson MA, Guerrant GO. Isoprenoid quinones of Campylobacter cryaerophila, C. cinaedi, C. fennelliae, C. hyointestinalis, C. pylori, and "C. upsaliensis". J Clin Microbiol 1990 28: 395 397.
35. Kelly DJ, Hughes NJ, Poole RK. Microaerobic physiology: aerobic respiration, anaerobic respiration, and carbon dioxide metabolism. In: Mobley HTL, Mendz GL, Hazell SL, eds. Helicobacter Pylori: Physiology and Genetic. Washington, D.C: ASM Press, 2001 113 124.
36. Suzuki A, Mitsuyama K, Koga H, Tomiyasu N, Masada J, Takaki K, Tsuruta O, Toyonaga A, Sata M. Bifidogenic growth stimulator for the treatment of active colitis: a pilot study. Nutrition 2006 22: 76 81.
37. Okada Y, Tsuzuki Y, Miyazaki J, et al. Propionibacterium freudenreichii component 1,4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 2007 55: 681 688.